USE OF CREATINE OR CREATINE ANALOGS FOR THE TREATMENT OF HUNTIGTON'S DISEASE, PARKINSON'S DISEASE AND AMYOTROPHIC LATERAL SCLEROSIS
    3.
    发明授权
    USE OF CREATINE OR CREATINE ANALOGS FOR THE TREATMENT OF HUNTIGTON'S DISEASE, PARKINSON'S DISEASE AND AMYOTROPHIC LATERAL SCLEROSIS 失效
    肌酸OR KREATINANOLOGEN的亨廷顿舞蹈病,帕金森氏病和肌萎缩性侧索硬化的治疗中

    公开(公告)号:EP0804183B1

    公开(公告)日:2006-07-05

    申请号:EP95939858.7

    申请日:1995-11-07

    摘要: The present invention relates to the use of creatine compounds including creatine, creatine phosphate or analogs of creatine, such as cyclocreatine, for treating diseases of the nervous system. Creatine compounds can be used as therapeutically effective agents against a variety of diseases of the nervous system such as diabetic and toxic neuropathies, peripheral nervous system diseases, Alzheimer disease, Parkinson's disease, stroke, Huntington's disease, motor neuron disease, traumatic nerve injury, multiple sclerosis, dysmyelination and demyelination disorders, and mitochondrial diseases. The Creatine compounds which can be used in the present method include: (1) creatine, creatine phosphate and analogs of these compounds which can act as substrates or substrate analogs for creatine kinase; (2) bisubstrate inhibitors of creatine kinase comprising covalently linked structural analogs of adenosine triphosphate (ATP) and creatine; (3) creatine analogs which can act as reversible or irreversible inhibitors of creatine kinase; and (4) N-phosphorocreatine analogs bearing non-transferable moieties which mimic the N-phosphoryl group.

    COMPOSITIONS CONTAINING A COMBINATION OF A CREATINE COMPOUND AND A SECOND AGENT
    4.
    发明公开
    COMPOSITIONS CONTAINING A COMBINATION OF A CREATINE COMPOUND AND A SECOND AGENT 审中-公开
    肌酸连接和第二物质组合物的组合

    公开(公告)号:EP1065931A1

    公开(公告)日:2001-01-10

    申请号:EP99915245.7

    申请日:1999-04-02

    CPC分类号: A61K45/06 A61K31/195

    摘要: The present invention relates to the use of creatine compound and neuroprotective combinations including creatine, creatine phosphate or analogs of creatine, such as cyclocreatine, for treating diseases of the nervous system. Creatine compounds in combination with neuroprotective agents can be used as therapeutically effective compositions against a variety of diseases of the nervous system such as diabetic and toxic neuropathies, peripheral nervous system diseases, Alzheimer disease, Parkinson's disease, stroke, Huntington's disease, amyotropic lateral sclerosis, motor neuron disease, traumatic nerve injury, multiple sclerosis, dysmyelination and demyelination disorders, and mitochondrial diseases. The creatine compounds which can be used in the present method include (1) creatine, creatine phosphate and analogs of these compounds which can act as substrates or substrate analogs for creatine kinase; (2) bisubstrate inhibitors of creatine kinase comprising covalently linked structural analogs of adenosine triphosphate (ATP) and creatine; (3) creatine analogs which can act as reversible or irreversible inhibitors of creatine kinase; and (4) N-phosphorocreatine analogs bearing non-transferable moieties which mimic the N-phosphoryl group.